CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 101 enrolled
Drug / intervention
Restylane-L® +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03460158
NCT03460158Phase 4Completed
CompareCT.gov

Prospective Evaluation of Minimally Invasive Facial Cosmetic Procedures Through Measured Volumetric Changes and Patient Reported Outcomes

University of Pennsylvania·interventional·Posted Mar 9, 2018·Updated Sep 27, 2024

In Brief

A Phase 4 clinical trial evaluating Restylane-L®, Restylane-L® Lyft, and 1 other intervention for Cosmetic Techniques. Completed, enrolled 101 participants across 1 site.

Detailed Summary

A prospective, trial to quantitatively and qualitatively compare the dermal fillers for the treatment of age related aesthetic changes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCosmetic Techniques
CountriesUnited States
CollaboratorsGalderma R&D

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedMar 9, 2018
Enrollment StartAug 21, 2020
Primary CompletionFeb 28, 2024
Study CompletionMay 29, 2024
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 8.3 years ago

Interventions

Restylane-L®drug

Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.

Restylane-L® Lyftdrug

Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).

Restylane Silk®drug

Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.